Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Blood
; 143(20): 2059-2072, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
3.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
4.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
Cancer
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38804723
5.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
6.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Cancer
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38809547
7.
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
Cancer
; 2024 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38896064
8.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 204(6): 2259-2263, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
9.
Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes.
J Antimicrob Chemother
; 79(2): 297-306, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38073151
10.
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
Mod Pathol
; 37(2): 100406, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104892
11.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
12.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
13.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Am J Hematol
; 99(5): 836-843, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400519
14.
Pre-emptive Aortic Side Branch Embolization during Endovascular Aneurysm Repair Using the Excluder Stent-Graft System: A Prospective Multicenter study.
J Vasc Interv Radiol
; 35(6): 874-882, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38479451
15.
Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Bioorg Med Chem Lett
; 108: 129799, 2024 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754564
16.
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
Acta Haematol
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38574468
17.
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Cancer
; 129(23): 3805-3814, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769040
18.
The role of therapy in the outcome of patients with myelofibrosis.
Cancer
; 129(18): 2828-2835, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243913
19.
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Cancer
; 129(12): 1866-1872, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882573
20.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426